| Literature DB >> 30422821 |
Bertrand Boisson1,2,3, Yoshitaka Honda4, Masahiko Ajiro5,6, Jacinta Bustamante1,2,3,7, Matthieu Bendavid1, Andrew R Gennery8, Yuri Kawasaki9, Jose Ichishima9, Mitsujiro Osawa9, Hiroshi Nihira4, Takeshi Shiba4, Takayuki Tanaka4, Maya Chrabieh2,3, Benedetta Bigio1, Hong Hur10, Yuval Itan1,11,12, Yupu Liang10, Satoshi Okada13, Kazushi Izawa4, Ryuta Nishikomori4, Osamu Ohara14,15, Toshio Heike4,16, Laurent Abel1,2,3, Anne Puel1,2,3, Megumu K Saito9, Jean-Laurent Casanova1,2,3,17,18, Masatoshi Hagiwara5,6, Takahiro Yasumi4.
Abstract
X-linked dominant incontinentia pigmenti (IP) and X-linked recessive anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) are caused by loss-of-function and hypomorphic IKBKG (also known as NEMO) mutations, respectively. We describe a European mother with mild IP and a Japanese mother without IP, whose 3 boys with EDA-ID died from ID. We identify the same private variant in an intron of IKBKG, IVS4+866 C>T, which was inherited from and occurred de novo in the European mother and Japanese mother, respectively. This mutation creates a new splicing donor site, giving rise to a 44-nucleotide pseudoexon (PE) generating a frameshift. Its leakiness accounts for NF-κB activation being impaired but not abolished in the boys' cells. However, aberrant splicing rates differ between cell types, with WT NEMO mRNA and protein levels ranging from barely detectable in leukocytes to residual amounts in induced pluripotent stem cell-derived (iPSC-derived) macrophages, and higher levels in fibroblasts and iPSC-derived neuronal precursor cells. Finally, SRSF6 binds to the PE, facilitating its inclusion. Moreover, SRSF6 knockdown or CLK inhibition restores WT NEMO expression and function in mutant cells. A recurrent deep intronic splicing mutation in IKBKG underlies a purely quantitative NEMO defect in males that is most severe in leukocytes and can be rescued by the inhibition of SRSF6 or CLK.Entities:
Keywords: Genetics; Infectious disease; Molecular diagnosis; NF-kappaB
Mesh:
Substances:
Year: 2018 PMID: 30422821 PMCID: PMC6355244 DOI: 10.1172/JCI124011
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808